Corcept Therapeutics Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2009 |
|---|---|---|---|---|---|---|---|
| Revenue | $159.2M | $81.3M | $50.3M | $26.6M | $10.4M | $3.3M | $29.0K |
| Cost of Revenue | $3.6M | $2.1M | $1.4M | $882.0K | $143.0K | $91.0K | — |
| Gross Profit | $155.6M | $79.3M | $48.9M | $25.7M | $10.2M | $3.2M | — |
| Gross Margin | 97.8% | 97.5% | 97.3% | 96.7% | 98.6% | 97.2% | — |
| Operating Expenses | |||||||
| Research & Development | $40.4M | $23.8M | $15.4M | $18.4M | $20.5M | $14.1M | $14.4M |
| SG&A Expense | $62.4M | $45.2M | $36.9M | $34.9M | $31.2M | $25.4M | $5.9M |
| Operating Income | $52.9M | $10.2M | $-3.4M | $-27.6M | $-41.5M | $-36.3M | $-20.3M |
| Operating Margin | 33.2% | 12.5% | -6.8% | -104.0% | -400.7% | -1,096.8% | -69,827.6% |
| Interest Expense | — | — | — | — | — | $1.7M | — |
| Pretax Income | $52.8M | $8.1M | $-6.4M | — | — | — | — |
| Income Tax Expense | $-76.3M | $0 | $0 | $0 | — | — | — |
| Net Income | $129.1M | $8.1M | $-6.4M | $-31.4M | $-46.0M | $-38.0M | $-20.2M |
| Net Margin | 81.1% | 10.0% | -12.7% | -118.2% | -444.3% | -1,150.5% | -69,537.9% |
| EPS (Basic) | $1.14 | $0.07 | $-0.06 | $-0.31 | $-0.46 | $-0.41 | $-0.38 |
| EPS (Diluted) | $1.04 | $0.07 | $-0.06 | $-0.31 | $-0.46 | $-0.41 | $-0.38 |
| Shares Outstanding (Basic) | 113.5M | 110.6M | 106.9M | 101.0M | 99.8M | 99.8M | — |
| Shares Outstanding (Diluted) | 124.5M | 116.1M | 106.9M | 101.0M | 99.8M | 99.8M | — |
| Dividends Per Share | — | — | — | — | $0.00 | — | — |